The US Food and Drug Administration (FDA) has approved Elekta's Leksell Gamma Knife Icon radiosurgery system.
Elekta is a Swedish company that provides radiation therapy, radiosurgery, related equipment and clinical management for the treatment of cancer and brain disorders.
With stereotactic imaging, online Adaptive DoseControl - a comprehensive concept that confirms accuracy and ensures precision of treatment delivery, ultra-precise dose delivery and the availability of frameless treatments, Icon is capable of treating virtually any target in the brain, regardless of type, location or volume.
The Icon represents the sixth generation of the company's Leksell Gamma Knife system, a technology that has been in use and continually evolving since the 1980s.
Gamma Knife radiosurgery is a gentler alternative to traditional brain surgery for illnesses such as metastatic disease.
The company claims that the system delivers up to thousands of low-intensity radiation beams to one or more targets in a single session with pinpoint accuracy.
Bill Yaeger, the company's Executive Vice President region North America, noted that Leksell Gamma Knife Icon offers a new model for the application of precise radiosurgery for a virtually unlimited range of cranial cases.
"Physicians have the flexibility to employ either frame-based or frameless techniques to immobilize the patient's head, in addition to the option to treat the patient in one session or multiple sessions. Importantly, Icon is the only system with the accuracy to enable ultra-precise Microradiosurgery in cases that demand the utmost precision," Yaeger added.